MTOR and hemangioma: First, TSC1 and TSC2 pathogenic mutations can lead to hemangioma formation through constitutively activated pathways of the mTOR pathway.[46] Second, the lower frequency of lymphatic involvement observed in patients with TSC-LAM may account for their mild pulmonary symptoms.[47]